20,104 Shares in Stryker Co. (NYSE:SYK) Acquired by Canada Post Corp Registered Pension Plan

Canada Post Corp Registered Pension Plan acquired a new position in Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 20,104 shares of the medical technology company's stock, valued at approximately $7,238,000.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Stryker by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock worth $11,773,213,000 after buying an additional 252,188 shares in the last quarter. FMR LLC raised its stake in Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after purchasing an additional 727,850 shares in the last quarter. Geode Capital Management LLC grew its stake in Stryker by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock worth $2,539,033,000 after buying an additional 168,436 shares in the last quarter. Norges Bank acquired a new position in shares of Stryker in the 4th quarter valued at approximately $1,710,744,000. Finally, Invesco Ltd. boosted its position in shares of Stryker by 15.3% during the 4th quarter. Invesco Ltd. now owns 2,007,105 shares of the medical technology company's stock worth $722,658,000 after acquiring an additional 266,587 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Trading Down 0.1 %

SYK traded down $0.21 during trading on Friday, hitting $346.46. The company's stock had a trading volume of 1,349,873 shares, compared to its average volume of 1,359,832. The firm has a market capitalization of $132.24 billion, a P/E ratio of 44.65, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The stock's fifty day moving average price is $370.95 and its 200-day moving average price is $373.04. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the firm posted $3.46 EPS. Analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio (DPR) is 43.30%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Canaccord Genuity Group boosted their price target on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a report on Wednesday, January 29th. Stifel Nicolaus raised their price target on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Royal Bank of Canada upped their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. JMP Securities restated a "market perform" rating on shares of Stryker in a research report on Tuesday, February 18th. Finally, StockNews.com downgraded shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $423.53.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.